-
Je něco špatně v tomto záznamu ?
Hirsutism--a low dose spironolactone therapy
M. Větr,
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
PubMed
2530821
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- folikuly stimulující hormon krev MeSH
- hirzutismus krev farmakoterapie etiologie MeSH
- lidé MeSH
- luteinizační hormon krev MeSH
- mladiství MeSH
- spironolakton aplikace a dávkování terapeutické užití MeSH
- testosteron krev MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Total testosterone, dehydroepiandrosterone sulfate, prolactin and estradiol were assayed in 78 women, clinically divided into idiopathic hirsutism (I. H.)-17 women and polycystic ovary syndrome (PCO) - 61 women, with the latter group having menstrual irregularity dating almost back to the menarche. The serum testosterone measurement was found to be not sensitive in detecting abnormalities in testosterone production. Only 24 (39%) of the women with polycystic ovary syndrome and 5 (29%) of the women with idiopathic hirsutism had elevated serum testosterone. In statistical analysis the serum testosterone was greater (P less than 0.05) in women with polycystic ovary syndrome without hirsutism than in idiopathic hirsutism and PCO with hirsutism. There were not significant differences between the mean levels of prolactin, dehydroepiandrosterone sulfate and estradiol. Twelve women, with hirsutism, were treated with low dose spironolactone (75 mg daily) for six months. There was an excellent clinical response in 7 (58%), incomplete response in one, no response in 4 women. Two patients dropped out of the trial because of ineffectiveness of the therapy after three months. Side effects were not major problem. Spironolactone caused statistically significant reduction in testosterone values after 6 months of treatment. Our results demonstrate that low-dose spironolactone is effective in the treatment of hirsutism.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19007976
- 003
- CZ-PrNML
- 005
- 20190301093304.0
- 007
- ta
- 008
- 190228s1989 xr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)2530821
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Větr, Miroslav $7 xx0105459
- 245 10
- $a Hirsutism--a low dose spironolactone therapy / $c M. Větr,
- 520 9_
- $a Total testosterone, dehydroepiandrosterone sulfate, prolactin and estradiol were assayed in 78 women, clinically divided into idiopathic hirsutism (I. H.)-17 women and polycystic ovary syndrome (PCO) - 61 women, with the latter group having menstrual irregularity dating almost back to the menarche. The serum testosterone measurement was found to be not sensitive in detecting abnormalities in testosterone production. Only 24 (39%) of the women with polycystic ovary syndrome and 5 (29%) of the women with idiopathic hirsutism had elevated serum testosterone. In statistical analysis the serum testosterone was greater (P less than 0.05) in women with polycystic ovary syndrome without hirsutism than in idiopathic hirsutism and PCO with hirsutism. There were not significant differences between the mean levels of prolactin, dehydroepiandrosterone sulfate and estradiol. Twelve women, with hirsutism, were treated with low dose spironolactone (75 mg daily) for six months. There was an excellent clinical response in 7 (58%), incomplete response in one, no response in 4 women. Two patients dropped out of the trial because of ineffectiveness of the therapy after three months. Side effects were not major problem. Spironolactone caused statistically significant reduction in testosterone values after 6 months of treatment. Our results demonstrate that low-dose spironolactone is effective in the treatment of hirsutism.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a folikuly stimulující hormon $x krev $7 D005640
- 650 _2
- $a hirzutismus $x krev $x farmakoterapie $x etiologie $7 D006628
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a luteinizační hormon $x krev $7 D007986
- 650 _2
- $a spironolakton $x aplikace a dávkování $x terapeutické užití $7 D013148
- 650 _2
- $a testosteron $x krev $7 D013739
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00011326 $t Acta Universitatis Palackianae Olomucensis Facultatis Medicae $x 0862-481X $g Roč. 122(1989), s. 239-245
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/2530821 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c sign $y a $z 0
- 990 __
- $a 20190228 $b ABA008
- 991 __
- $a 20190301093611 $b ABA008
- 999 __
- $a ok $b bmc $g 1380786 $s 1046224
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 1989 $b 122 $d 239-245 $i 0862-481X $m Acta Universitatis Palackianae Olomucensis Facultatis medicae. Biomedical papers $n Acta Univ. Palacki. Olomuc. Fac. med., Biomed. Pap. $x MED00011326
- LZP __
- $a Pubmed-20190228